#PhRMA14 Day 2 – “Imagine If"

#PhRMA14 Day 2 – “Imagine If"

04.10.14 | By

Day two of #PhRMA14 was chock full of insightful conversations focused on the current state of the biopharmaceutical industry and what it will take to continue to innovate. Our President and CEO kicked the day off by highlighting the industry’s commitment to collaboration, discussingprograms such as Genetic Alliance and AMP. Castellani reminded attendees that the future of the biopharmaceutical industry, and ultimately the livelihood of patients, rests on leaders’ ability to work together and adopt the mindset of “imagine if” rather than “remember when.” 

Echoing Castellani’s remarks on collaboration and forward looking progress, FDA Commissioner Margaret Hamburg discussed the agency’s desire to work with biopharmaceutical manufacturers earlier in the research and development process. “Science is the service of people,” noted Hamburg, and increased modes of communication and collaboration will only increase patients’ access to the treatments they need. 

We also heard from The Honorable Fred Upton (R-MI) and The Honorable Eric Cantor (R-VA). While they gave separate addresses, one theme was clear: It’s time Congress prioritize research to help improve the lives of all patients. Our goal is finding cures, and we need to work together through public and private partnerships to advance our R&D capabilities and innovation.

This year, we broke out our morning and afternoon panel sessions into three separate tracks. While various conversations were taking place both in the four walls of the meeting and online, collaboration among all sectors involved in the research and development process emerged as a continuing theme.

Our morning track sessions focused on addressing patient needs, such as increasing access to new medications on the market with a focus on quality and value. As patients are strengthening their voices within the industry, it’s important we work together to communicate the efforts of our industry as well as what’s currently in the pipeline to help improve the lives of patients around the world.

Our afternoon track sessions focused on opportunities to advance innovation and how important it is to both protect patients and our nation’s intellectual property rights. The opportunities for our industry are boundless when it comes to initiatives like big data research and international trade agreements, but we must prioritize the well-being of our patients through smart collaboration. As Castellani noted, the future of the biopharmaceutical industry will only progress if we work together and “imagine if.”

Check out a few highlights from today’s #PhRMA14 conversations online and join us again tomorrow morning at 8 a.m. EST.

Take a look at a few highlights from #PhRMA14 today!



Hide Comments